Clinical Trial

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.
Trial Details
NCT Number NCT07273396
Lead Sponsor Seoul National University Hospital
Conditions Ovarian Neoplasms, Peritoneal Neoplasms
Enrollment 53 participants
Start Date 2026-01-01
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-09